Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 14.84

From 52W high−49.14%

Volume7.02M

Market capCNY 4.46B

P/E (TTM)−45.4x

P/S (TTM)1.5x

Div yield0.47%

Key dataSep 18, 2026

Open

CNY 14.84

From 52W high

−49.14%

Volume

7.02M

Market cap

CNY 4.46B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

65.2x

P/E (TTM)

−45.4x

RSI (14)

39.2

MomentumView details →

1D Return

−6.01%

YTD Return

−18.90%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−45.4x

EV/EBITDA

65.2x

EV/Sales

2.0x

P/S (TTM)

1.5x

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

31.03%

Net Margin

−3.97%

EBITDA Margin

3.04%

ROE (TTM)

−8.99%

ROA (TTM)

−2.77%

Asset Turnover

0.70x

GrowthView details →

Revenue YoY

+28.10%

EPS YoY

—

FCF YoY

−13.31%

Revenue CAGR 3Y

+11.52%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−6.01%

YTD Return

−18.90%

1Y Return

−25.94%

RSI (14)

39.2

vs 50D SMA

−9.65%

vs 200D SMA

−21.35%

Capital & dividendView details →

Debt/Equity

1.06x

Current Ratio

0.94x

Quick Ratio

0.64x

Div Yield

0.47%

Div Rate

CNY 0.07

Div Growth 1Y

−21.35%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

2.89B

Net Income (TTM)

−114.97M

Op. CF (TTM)

−40.33M

Latest newsMore news →

Lianhuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 10.5218 million yuan, turning from a loss in the same period last year.23d ago

Lianhuan Pharmaceutical's board approved its subsidiary Lianhuan (Nanjing) Medical Technology to borrow 10 million yuan from related party Jiangsu Lianhuan Health Industry Management Development at an annual interest rate of 2.5% for up to 3 months.40d ago

Similar companies

ST中珠600568.SH 方盛制药603998.SH 健民集团600976.SH 太龙药业600222.SH Xuanzhubio-b02575.HK 千金药业600479.SH Find similar companies →

Latest newsMore news →

Lianhuan Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 10.5218 million yuan, turning from a loss in the same period last year.23d ago Lianhuan Pharmaceutical's board approved its subsidiary Lianhuan (Nanjing) Medical Technology to borrow 10 million yuan from related party Jiangsu Lianhuan Health Industry Management Development at an annual interest rate of 2.5% for up to 3 months.40d ago